{
    "name": "sparsentan",
    "comment": "Rx",
    "other_names": [
        "Filspari"
    ],
    "classes": [
        "Dual Endothelin Angiotensin Receptor Antagonists (DEARAs)"
    ],
    "source": "https://reference.medscape.com/drug/filspari-sparsentan-4000291",
    "pregnancy": {
        "common": [
            "Contraindicated in pregnant patients",
            "Based on animal data, can cause fetal harm, including birth defects and fetal death, when administered to pregnant females",
            "Verify patients of reproductive potential are not pregnant before initiating, monthly during treatment, and 1 month after discontinuing drug",
            "Advise pregnant patients of the potential risk to the fetus"
        ],
        "specific": [
            {
                "type": "Animal studies ",
                "description": [
                    "Oral administration to pregnant rats throughout organogenesis at 10 times the maximum recommended human dose in mg/day caused teratogenic effects in rats, including craniofacial malformations, skeletal abnormalities, increased embryo-fetal lethality, and reduced fetal weights"
                ]
            },
            {
                "type": "Contraception ",
                "description": [
                    "Patients of reproductive potential: Use an effective method of contraception before initiating, during treatment, and for 1 month after discontinuing"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Owing to risks of hepatotoxicity and birth defects, sparsentan is available only through a restricted program called the FILSPARI REMS",
                "Prescribers, patients, and pharmacies must enroll in the Risk Evaluation and Mitigation Strategies (REMS) program"
            ],
            "specific": [
                {
                    "type": "Hepatotoxicity ",
                    "description": [
                        "Some endothelin receptor antagonists (ERAs) have caused elevations of aminotransferases (ALT, AST), hepatotoxicity, and liver failure",
                        "In clinical studies, elevations of ALT or AST of â‰¥3x ULN observed in up to 2.5% of treated patients, including cases confirmed with rechallenge",
                        "Measure transaminases and bilirubin before initiating and monthly for first 12 months of treatment, and then every 3 months during treatment",
                        "Interrupt treatment and closely monitor if aminotransferase elevations >3x ULN",
                        "Avoid use in patients with elevated aminotransferases at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at increased risk for serious hepatotoxicity"
                    ]
                },
                {
                    "type": "Embryofetal toxicity ",
                    "description": [
                        "Can cause major birth defects if used by pregnant patients, based on animal data",
                        "Pregnancy testing is required before initiating treatment, during treatment, and 1 month after discontinuation",
                        "Patients who can become pregnant must use effective contraception before the initiation of treatment, during treatment, and for 1 month after discontinuation"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aliskiren",
            "description": {
                "common": "sparsentan, aliskiren.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of aliskiren with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ambrisentan",
            "description": {
                "common": "sparsentan, ambrisentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of endothelin antagonists with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aprocitentan",
            "description": {
                "common": "sparsentan, aprocitentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of endothelin antagonists with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "azilsartan",
            "description": {
                "common": "sparsentan, azilsartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bosentan",
            "description": {
                "common": "sparsentan, bosentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of endothelin antagonists with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "candesartan",
            "description": {
                "common": "sparsentan, candesartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eprosartan",
            "description": {
                "common": "sparsentan, eprosartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "irbesartan",
            "description": {
                "common": "sparsentan, irbesartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "losartan",
            "description": {
                "common": "sparsentan, losartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "macitentan",
            "description": {
                "common": "sparsentan, macitentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of endothelin antagonists with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "olmesartan",
            "description": {
                "common": "sparsentan, olmesartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "sparsentan, sacubitril/valsartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "telmisartan",
            "description": {
                "common": "sparsentan, telmisartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "valsartan",
            "description": {
                "common": "sparsentan, valsartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. H2-antagonists may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "dexlansoprazole decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Proton pump inhibitors may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Proton pump inhibitors may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "famotidine",
            "description": {
                "common": "famotidine decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. H2-antagonists may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "irinotecan",
            "description": {
                "common": "sparsentan will increase the level or effect of irinotecan by  Other (see comment). Avoid or Use Alternate Drug. Sparsentan (a BCRP inhibitor) may increase exposure of sensitive BCRP substrates and the risk of these substrates toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "lansoprazole decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Proton pump inhibitors may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methotrexate",
            "description": {
                "common": "sparsentan will increase the level or effect of methotrexate by  Other (see comment). Avoid or Use Alternate Drug. Sparsentan (a BCRP inhibitor) may increase exposure of sensitive BCRP substrates and the risk of these substrates toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of sparsentan by  affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nizatidine",
            "description": {
                "common": "nizatidine decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. H2-antagonists may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Proton pump inhibitors may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pantoprazole",
            "description": {
                "common": "pantoprazole decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Proton pump inhibitors may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "rabeprazole decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Proton pump inhibitors may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ranitidine",
            "description": {
                "common": "ranitidine decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. H2-antagonists may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "topotecan",
            "description": {
                "common": "sparsentan will increase the level or effect of topotecan by  Other (see comment). Avoid or Use Alternate Drug. Sparsentan (a BCRP inhibitor) may increase exposure of sensitive BCRP substrates and the risk of these substrates toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib, sparsentan.\nEither increases levels of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adagrasib",
            "description": {
                "common": "adagrasib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer sparsentan 2 hours before or after administration of antacids. Antacids may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "sparsentan and amiloride both increase  serum potassium. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "aspirin rectal and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer sparsentan 2 hours before or after administration of antacids. Antacids may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "sparsentan will decrease the level or effect of avapritinib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avatrombopag",
            "description": {
                "common": "sparsentan will decrease the level or effect of avatrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "sparsentan will decrease the level or effect of belzutifan by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bicalutamide",
            "description": {
                "common": "bicalutamide will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bortezomib",
            "description": {
                "common": "sparsentan will decrease the level or effect of bortezomib by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brivaracetam",
            "description": {
                "common": "sparsentan will decrease the level or effect of brivaracetam by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "sparsentan will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer sparsentan 2 hours before or after administration of antacids. Antacids may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "sparsentan will decrease the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "sparsentan will decrease the level or effect of carisoprodol by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "sparsentan will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "sparsentan will decrease the level or effect of chlorpropamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "choline magnesium trisalicylate and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "sparsentan will decrease the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "sparsentan will decrease the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "sparsentan will decrease the level or effect of clomipramine by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clotrimazole",
            "description": {
                "common": "clotrimazole will increase the level or effect of sparsentan by  affecting hepatic enzyme CYP2E1 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "sparsentan will decrease the level or effect of cyclophosphamide by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "sparsentan will decrease the level or effect of dapsone by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desogestrel",
            "description": {
                "common": "sparsentan will decrease the level or effect of desogestrel by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of dexlansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "sparsentan will decrease the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "sparsentan will decrease the level or effect of diazepam intranasal by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "diclofenac and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronabinol",
            "description": {
                "common": "sparsentan will decrease the level or effect of dronabinol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "sparsentan and drospirenone both increase  serum potassium. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "sparsentan will decrease the level or effect of efavirenz by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "entacapone",
            "description": {
                "common": "entacapone will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "sparsentan will decrease the level or effect of erdafitinib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "sparsentan will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "etodolac and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "sparsentan will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "fenoprofen and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "sparsentan will decrease the level or effect of flibanserin by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "sparsentan will decrease the level or effect of fluoxetine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "flurbiprofen and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "sparsentan will decrease the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "sparsentan will decrease the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fospropofol",
            "description": {
                "common": "sparsentan will decrease the level or effect of fospropofol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "fostamatinib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "sparsentan will decrease the level or effect of glimepiride by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "sparsentan will decrease the level or effect of glipizide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "sparsentan will decrease the level or effect of glyburide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrexafungerp",
            "description": {
                "common": "ibrexafungerp will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "ibuprofen and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "ibuprofen IV and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen/famotidine",
            "description": {
                "common": "ibuprofen/famotidine and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "sparsentan will decrease the level or effect of ifosfamide by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "sparsentan will decrease the level or effect of imatinib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "sparsentan will decrease the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "indomethacin and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan",
            "description": {
                "common": "sparsentan will decrease the level or effect of irinotecan by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "sparsentan will decrease the level or effect of ketamine by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "ketoprofen and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "ketorolac and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "ketorolac intranasal and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lacosamide",
            "description": {
                "common": "sparsentan will decrease the level or effect of lacosamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lesinurad",
            "description": {
                "common": "sparsentan will decrease the level or effect of lesinurad by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "sparsentan will decrease the level or effect of lonafarnib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "sparsentan will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magaldrate",
            "description": {
                "common": "magaldrate decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer sparsentan 2 hours before or after administration of antacids. Antacids may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "magnesium oxide decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer sparsentan 2 hours before or after administration of antacids. Antacids may decrease sparsentan exposure which may reduce efficacy of sparsentan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mavacamten",
            "description": {
                "common": "sparsentan will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "mefenamic acid and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "meloxicam and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mephobarbital",
            "description": {
                "common": "sparsentan will decrease the level or effect of mephobarbital by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methohexital",
            "description": {
                "common": "sparsentan will decrease the level or effect of methohexital by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methsuximide",
            "description": {
                "common": "sparsentan will decrease the level or effect of methsuximide by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miconazole oral",
            "description": {
                "common": "sparsentan will decrease the level or effect of miconazole oral by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "modafinil",
            "description": {
                "common": "sparsentan will decrease the level or effect of modafinil by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "montelukast",
            "description": {
                "common": "sparsentan will decrease the level or effect of montelukast by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "nabumetone and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "naproxen and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "sparsentan will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "sparsentan will decrease the level or effect of nelfinavir by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "netupitant/palonosetron will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omeprazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of omeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "sparsentan will decrease the level or effect of ospemifene by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "oxaprozin and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pantoprazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "sparsentan will increase the level or effect of pentamidine by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "sparsentan will increase the level or effect of phenobarbital by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "sparsentan will decrease the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "piroxicam and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "sparsentan and potassium acid phosphate both increase  serum potassium. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "sparsentan and potassium chloride both increase  serotonin levels. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "sparsentan and potassium citrate both increase  serotonin levels. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone intravaginal gel",
            "description": {
                "common": "sparsentan will decrease the level or effect of progesterone intravaginal gel by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "sparsentan will decrease the level or effect of progesterone micronized by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "sparsentan will decrease the level or effect of promethazine by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "sparsentan will decrease the level or effect of propofol by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinupristin/dalfopristin",
            "description": {
                "common": "quinupristin/dalfopristin will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of rabeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "sparsentan will decrease the level or effect of rifampin by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "salsalate and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "schisandra",
            "description": {
                "common": "schisandra will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "sparsentan will decrease the level or effect of selegiline by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "sparsentan will decrease the level or effect of siponimod by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "sparsentan and spironolactone both increase  serum potassium. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "sparsentan will decrease the level or effect of sulfadiazine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of sulfisoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "sulindac and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "sparsentan will decrease the level or effect of tamoxifen by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "sparsentan will decrease the level or effect of tofacitinib by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "sparsentan will decrease the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "tolmetin and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "sparsentan will decrease the level or effect of torsemide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamterene",
            "description": {
                "common": "sparsentan and triamterene both increase  serum potassium. Use Caution/Monitor. Monitor serum potassium frequently."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "sparsentan will decrease the level or effect of trimethoprim by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "sparsentan will decrease the level or effect of trimipramine by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "velpatasvir",
            "description": {
                "common": "sparsentan will decrease the level or effect of velpatasvir by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "sparsentan will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "sparsentan will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "sparsentan will decrease the level or effect of zafirlukast by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates. "
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Peripheral edema",
            "percent": "14"
        },
        {
            "name": "Hypotension",
            "percent": "14"
        },
        {
            "name": "including orthostatic hypotension",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "13"
        },
        {
            "name": "Hyperkalemia",
            "percent": "5"
        },
        {
            "name": "Anemia",
            "percent": "4"
        },
        {
            "name": "Acute kidney injury",
            "percent": "2.5"
        },
        {
            "name": "Transaminase elevations",
            "percent": null
        }
    ]
}